Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle ® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for ...

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where Bicycle Therapeutics (NASDAQ:BCYC) stands against other high growth UK ...

There is a major inflection point expected to happen with Bicycle Therapeutics plc (BCYC) in the 2nd half of 2024. That is when it expects to complete dosing of its open-label phase 1/2 Duravelo-1 ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

The Mercedes-AMG PETRONAS Formula One Team, in collaboration with its licensed partner n+, has launched an innovative series of e-bikes, setting a new benchmark for electric bicycle technology.

This content was paid for by an advertiser and created by Crain's Custom Content. TIME Bicycles, in partnership with KraussMaffei, Fraunhofer USA and Clemson University is raising the bar of composite ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Fifty two years after Scientific American first declared a human propelling a bicycle to coasting speed more efficient than salmon, seagulls, or jet planes, the august magazine has revisited an iconic ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...

Phase 2/3 Duravelo-2 pivotal trial evaluating zelenectide pevedotin (zelenectide) plus pembrolizumab in metastatic urothelial cancer (mUC) successfully identifies 6mg/m2 zelenectide two weeks on, one ...